Jones Financial Companies
CLRB icon

Jones Financial Companies’s Cellectar Biosciences CLRB Stock Holding History

Jones Financial Companies’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8 Hold
3
– – ﹤0.01% 4704
2025
Q4 		$9 Hold
3
– – ﹤0.01% 4378
2025
Q3 		$17 Hold
3
– – ﹤0.01% 4203
2025
Q2 		$24 Buy
+3
New +$26 ﹤0.01% 3994

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Jones Financial Companies's CLRB Position: Q1 2026 in Review

Jones Financial Companies held its Cellectar Biosciences (CLRB) position steady in Q1 2026 at 3 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #4704.

Jones Financial Companies first reported a position in CLRB in Q2 2025 and has held it in 4 quarters since. The position peaked at $24 in Q2 2025. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

  • Jones Financial Companies held 3 shares of Cellectar Biosciences worth $8 as of Q1 2026.
  • Jones Financial Companies left its Cellectar Biosciences share count unchanged in Q1 2026.
  • Cellectar Biosciences made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4704 holding.
  • Jones Financial Companies first reported a position in Cellectar Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Jones Financial Companies's Cellectar Biosciences position peaked at $24 in Q2 2025.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.